

Empowering Personalised Treatment of Breast Cancer Patients

RadioVal implements the first international, clinical validation study of radiomics-based prediction of neoadjuvant chemotherapy treatment response from breast MRI.

RadioVal develops a comprehensive and standardised methodological framework for multi-faceted radiomics evaluation. We will promote precision medicine with tools that provide insights into decision-making and AI performance through time.

RadioVal will help clinicians develop treatment plans tailored to each patient, potentially reducing the costs of breast cancer care.

In dialogue with healthcare professionals, patients, AI developers and ethicolegal experts, we will design the evaluation study according to their needs and requirements. We will then perform the evaluation study on real-world data from eight hospitals all over the world.

"We noticed a lot of AI tools were of very good quality with interesting results, but not sufficiently translated into clinical practice because there was a lack of evidence they could be trusted in the real world."

- Karim Lekadir, University of Barcelona, **RadioVal** Coordinator

www.radioval.eu

radioval

radioval

Visit www.radioval.eu for more information.

The **RadioVal** consortium is a highly experienced and ambitious consortium with a unique blend of assets and expertise suited to achieve the ambitious objective of a first multi-faceted, international validation study in the field of radiomics.

Contact us:

e-mail: radioval@eibir.org

Twitter: [@RadioVal_AI](https://twitter.com/RadioVal_AI)

Website: www.radioval.eu

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057699.



**Funded by
the European Union**